Molecular Breast Imaging

The Dilon Molecular Imaging System is a specialized camera designed to image various organs. This system has been optimized to perform Molecular Breast Imaging (MBI) and is a strong diagnostic tool in early breast cancer detection. Using MBI as an adjunct to mammography results in an almost fourfold increase in invasive cancer detection in women with dense breast tissue. MBI has a higher specificity than MRI and has proven to reduce benign biopsies by 50%. With a negative predictive value of 98% MBI is the beacon in dense breast tissue. The system offers MBI biopsy capability which provides an additional tool to accurately localize the region of interest.

The Dilon MBI procedure is an excellent problem-solving tool when faced with difficult-to-diagnose patients with:

What can MBI do?

For the breast radiologist:

For the breast surgeon:

How Does MBI Work?

MBI uses a pharmaceutical tracer that is absorbed by the breast tissue. The cancerous cells in the breast absorb a greater amount of the tracer than normal, healthy cells.  As a result, the tracer “lights up” the cancerous areas inside the breast and the malignant cells appear as “dark spots” on the MBI image. Patients find the exam to be very comfortable, unlike mammography, as there is minimal compression and they are seated throughout the process.

Its similarity to mammographic positioning makes the MBI an easy modality for any trained mammographer to learn and use, and allows easy comparison to the original mammography views by the radiologist. The breast cancer scanning procedure may begin five minutes after the patient has been injected with a small amount of radioactive tracer (Tc-99m Sestamibi). The entire breast cancer screening study takes approximately 40-45 minutes and images are immediately available for a physician’s interpretation.

MBI Clinical Aspects

The Dilon Molecular Breast Imaging (MBI) Procedure can detect cancers missed by mammography and ultrasound, while leading to fewer benign biopsies than MRI. According to clinical studies, MBI has very high sensitivity for identifying earlier stage cancers as small as 1 mm. Clinical indications of MBI include:

Dilon Partners